CytoSorbents Corporation (CTSO)

[eColi]

http://www.lulegacy.com/2015/08/19/insider-selling-cytosorbents-corp-director-sells-62600-00-in-stock-ctso/584892/

Director Al Kraus sold 10,000 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $6.26, for a total transaction of $62,600.00. Following the sale, the director now owns 55,746 shares in the company, valued at approximately $348,969.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Several equities research analysts have commented on CTSO shares. Brean Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Cytosorbents Corp in a research note on Monday. MLV & Co. reduced their target price on shares of Cytosorbents Corp from $28.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $16.32.

Shares of Cytosorbents Corp (OTCMKTS:CTSO) traded down 3.51% during mid-day trading on Wednesday, reaching $7.43. 32,551 shares of the company were exchanged. The stock’s market capitalization is $186.09 million. Cytosorbents Corp has a 12 month low of $4.40 and a 12 month high of $15.24. The firm has a 50-day moving average price of $6.51 and a 200 day moving average price of $8.01.

Cytosorbents Corp (OTCMKTS:CTSO) last posted its quarterly earnings results on Thursday, August 13th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters consensus estimate of ($0.11) by $0.16. The firm had revenue of $1.69 million for the quarter. Equities research analysts anticipate that Cytosorbents Corp will post ($0.40) EPS for the current fiscal year.

CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses. The technology is based upon biocompatible, highly porous polymer sorbent beads that are capable of extracting unwanted substances, such as drugs, dangerous chemicals, toxins, cytokines, free hemoglobin, and antibodies, from blood and other bodily fluids. Its CE Mark enables CytoSorb to be sold throughout the entire European Union. In addition to the sepsis indication, the Company continues to foster research in other critical care illnesses where CytoSorb could be used, such as ARDS, trauma, severe burn injury, acute pancreatitis, and in other acute conditions that may benefit by the reduction of cytokines in the bloodstream.